ascorbic-acid and Virus-Diseases

This study performed a meta-analysis to explore the clinical efficacy of creatine phosphate sodium (CPS) and/or vitamin C for viral myocarditis (VMC) in children, to provide guidance for its clinical treatment.. A literature search was performed on PubMed, Web of Science, Embase, China National Knowledge Infrastructure, and Wanfang databases to obtain published clinical randomized controlled trials (RCTs) on CPS and/or vitamin C for VMC in children, with a time span from 2013 to 2022. Relevant data was extracted and meta-analysis was performed using the statistical software Stata 16.0.. A total of 723 studies were retrieved and 19 studies were finally included for meta-analysis, with a total of 1,957 patients. The meta-analysis results showed that the observation group (conventional treatment + CPS and/or vitamin C) was superior to the control group (conventional treatment alone) in treatment effective rate (OR = 3.60, 95% CI (2.55, 5.07), and. CPS and/or vitamin C treatment could greatly improve the treatment, protect myocardial function, and relieve inflammatory response in children with VMC.

Topics: Ascorbic Acid; Aspartate Aminotransferases; Child; Humans; Myocarditis; Phosphocreatine; Sodium; Treatment Outcome; Virus Diseases

Vitamins are essential to maintain normal metabolic processes and homeostasis within the body. The amount of a specific vitamin required by an individual varies considerably and it is influenced by such factors as body size, growth rate, physical activity, and pregnancy. Most vitamins are stored minimally in human cells, but some are stored in liver cells to a greater extent. Vitamins A and D, for example, may be stored in sufficient amounts to maintain an individual without any intake for 5 to 10 months and 2 to 4 months, respectively. However, a deficiency of vitamin B compounds (except vitamin B12) may be noted within days, and the lack of vitamin C will manifest within weeks and may result in death in 5 to 6 months. The current recommended dietary allowance (RDA) of vitamin C is 75 mg for woman and 90 mg for men, based on the vitamin's role as an antioxidant as well as protection from deficiency. High intakes of the vitamin are generally well tolerated, however, a Tolerable Upper Level (TUL) was recently set at 2 g based on gastrointestinal upset that sometimes accompanies excessive dosages. Several populations warrant special attention with respect to vitamin C requirements. These include patients with periodontal disease, smokers, pregnant and lactating women, and the elderly.

Topics: Alzheimer Disease; Animals; Antioxidants; Ascorbic Acid; Ascorbic Acid Deficiency; Bone Regeneration; Cardiovascular Diseases; Chondrogenesis; Diabetes Mellitus; Female; Humans; Male; Maximum Tolerated Dose; Nutrition Policy; Periodontal Diseases; Pregnancy; Virus Diseases

Potentially damaging species (reactive oxygen, nitrogen and chlorine species) arise as by-products of metabolism and as physiological mediators and signalling molecules. Levels of these species are controlled by the antioxidant defence system. Several components of this system are micronutrients (e.g. vitamins C and E) or are dependent upon dietary micronutrients (e.g. CuZn and Mn superoxide dismutase). The antioxidant defences act as a coordinated system where deficiencies in one component may affect the efficiency of the others. Oxidative stress may be an important factor in infection if micronutrients are deficient.

Topics: Antioxidants; Arthritis, Rheumatoid; Ascorbic Acid; Cardiovascular Diseases; Copper; Deficiency Diseases; Developing Countries; Disease Susceptibility; HIV Infections; Humans; Iron; Magnesium; Manganese; Micronutrients; Nutritional Status; Oxidative Stress; Virus Diseases; Vitamin E; Zinc

Topics: Adjuvants, Immunologic; Animals; Antiviral Agents; Ascorbic Acid; Cell Adhesion; Chemotaxis, Leukocyte; Humans; In Vitro Techniques; Neutrophils; Phagocytes; Respiratory Burst; Virus Diseases; Virus Replication

Immune modulators have exhibited some limited efficacy in the prevention or treatment of viral infection. Such agents have included transfer factor, thymosin, thymic humoral factors, levamisole, isoprinosine, immune RNA, young lymphocytes, vitamin C, and BCG. This article focuses on data that have examined clinical application of immune adjuvant therapy.

Topics: Adjuvants, Immunologic; Animals; Ascorbic Acid; BCG Vaccine; Humans; Inosine Pranobex; Levamisole; Lymphocyte Transfusion; RNA; Thymus Hormones; Transfer Factor; Virus Diseases

Topics: Amantadine; Antiviral Agents; Ascorbic Acid; Dosage Forms; Drug Evaluation; Encephalitis; Hepatitis; Herpes Simplex; Herpes Zoster; Humans; Idoxuridine; Influenza, Human; Inosine Pranobex; Interferons; Levamisole; Rimantadine; Subacute Sclerosing Panencephalitis; Trifluridine; Virus Diseases

Topics: Adult; Anaphylaxis; Animals; Antibody Formation; Ascorbic Acid; Autoimmune Diseases; Bacterial Infections; Chemotaxis; Common Cold; Female; Humans; Immunity, Cellular; Male; Phagocytes; Phagocytosis; T-Lymphocytes; Virus Diseases

Topics: Animals; Antibodies, Viral; Antibody Formation; Ascorbic Acid; Bacteriophages; Binding Sites; DNA Viruses; DNA, Viral; Free Radicals; Humans; Interferons; Oxidation-Reduction; Virus Diseases; Viruses

Topics: Adenoviridae; Antiviral Agents; Ascorbic Acid; Cold Temperature; Common Cold; Disease Outbreaks; Enterovirus; Humans; Interferons; Orthomyxoviridae; Respirovirus; Rhinovirus; Vaccination; Virus Diseases; Viruses

Topics: Adult; Amantadine; Animals; Antiviral Agents; Ascorbic Acid; Child; Cytopathogenic Effect, Viral; DNA, Viral; Fusidic Acid; Guanidines; Humans; Infant; Interferons; Isoquinolines; Middle Aged; Respiratory Tract Infections; RNA, Viral; Streptococcal Infections; Virus Cultivation; Virus Diseases; Viruses

Ancillary therapy (ANC) is commonly provided in conjunction with an antimicrobial when treating calves for suspected bovine respiratory disease (BRD) in an attempt to improve the response to a suspected BRD challenge. The first experiment evaluated the effects of 3 ANC in combination with an antimicrobial in high-risk calves treated for BRD during a 56-d receiving period. Newly received crossbred steers (n = 516; initial BW = 217 ± 20 kg) were monitored by trained personnel for clinical signs of BRD. Calves that met antimicrobial treatment criteria (n = 320) were then randomly assigned to experimental ANC treatment (80 steers/experimental ANC treatment): intravenous flunixin meglumine injection (NSAID), intranasal viral vaccination (VACC), intramuscular vitamin C injection (VITC), or no ANC (NOAC). Animal served as the experimental unit for all variables except DMI and G:F (pen served as the experimental unit for DMI and G:F). Within calves treated 3 times for BRD, those receiving NOAC had lower (P < 0.01) clinical severity scores (severity scores ranged from 0 to 4 on the basis of observed clinical signs and severity) and heavier (P = 0.01) BW than those receiving NSAID, VACC, or VITC at the time of third treatment. Between the second and third BRD treatments, calves receiving NOAC had decreased (P < 0.01) daily BW loss (−0.13 kg ADG) compared with those receiving NSAID, VACC, or VITC (−1.30, −1.90, and −1.41 kg ADG, respectively). There were no differences in rectal temperature, combined mortalities and removals, or overall performance among the experimental ANC treatments. Overall, morbidity and mortality attributed to BRD across treatments were 66.5% and 13.2%, respectively. After the receiving period, a subset of calves (n = 126) were allocated to finishing pens to evaluate the effects ANC administration on finishing performance, carcass characteristics, and lung scores at harvest. Ultrasound estimates, BW, and visual appraisal were used to target a common physiological end point for each pen of calves. There were no differences among the experimental ANC observed during the finishing period (P ≥ 0.11). In summary, the use of NSAID, VACC, and VITC do not appear to positively impact clinical health and could potentially be detrimental to performance during the receiving period in high-risk calves receiving antimicrobial treatment for suspected BRD.

Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Ascorbic Acid; Body Weight; Bovine Respiratory Disease Complex; Cattle; Clonixin; Drug Therapy, Combination; Injections, Intravenous; Male; Viral Vaccines; Virus Diseases

Topics: Adult; Ascorbic Acid; Drug Therapy, Combination; Drugs, Chinese Herbal; Female; Humans; Infusions, Intravenous; Male; Myocarditis; Phytotherapy; Virus Diseases

The results of a clinical trial of a new presentation designed for pediatric patients in 29 children are reported. Rectal temperature was recorded every 3 hours, for 12 hours. Patients were given a 12 mg/kg dose every 6 hours. A significant and satisfactory decrease in body temperature was observed. No undesirable side effects were recorded.

Topics: Acetaminophen; Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Ascorbic Acid; Bacterial Infections; Child, Preschool; Clinical Trials as Topic; Drug Combinations; Female; Fever; Humans; Male; Solutions; Virus Diseases

Topics: Adenoviridae Infections; Ascorbic Acid; Citrates; Clinical Trials as Topic; Common Cold; Humans; Influenza, Human; Leukocytes; Placebos; Respiratory Tract Infections; Virus Diseases

Topics: Animals; Antiviral Agents; Ascorbic Acid; Humans; Virus Diseases; Vitamins

Three hundred and fifty children at the age of 3 months to 6 years under diverse social conditions were observed in dynamics for the periods of 1 to 3 years. The main tasks of the study were development of schemes and methods for prophylactic use of the Viferon ointment and estimation of its efficacy in acute viral respiratory tract infection. Season changes in the interferon genesis were revealed and no such dynamics in the children with frequent infections was shown. The ointment was applied according to the developed procedure intranasally in a daily dose of 1 g every day for the first 2 weeks and 3 times a week for the following 2-4 weeks. Interferon correctable and immunomodulating effects of the ointment were detected, the same as its favourable impact on the number of the acute respiratory tract infection cases including those under the conditions of the infant school adaptation. Its favourable effect was also observed in children with frequent infections during their immunorehabilitation. The most pronounced clinical and immunomodulating effects were revealed in young children.

Topics: Acute Disease; Antiviral Agents; Ascorbic Acid; Child; Child, Preschool; Female; Humans; Infant; Interferon alpha-2; Interferon-alpha; Male; Ointments; Recombinant Proteins; Respiratory Tract Infections; Retrospective Studies; Virus Diseases; Vitamin E

High dose intravenous(i.v.) ascorbic acid (AA) has been used as therapy for infectious disease from bacterial and viral origin and adjuvant therapy for cancer. In this publication we describe a clinical protocol that has been developed over the past twenty years utilizing high dose i.v. AA as therapy for cancer. This includes principles of treatment, rationale, baseline workup, infusion protocol, precautions and side effects.

Topics: Anti-Infective Agents; Antineoplastic Agents; Ascorbic Acid; Bacterial Infections; Clinical Protocols; Dose-Response Relationship, Drug; Humans; Infusions, Intravenous; Neoplasms; Neoplastic Stem Cells; Virus Diseases

Topics: Ascorbic Acid; Carnitine; Endocrine System Diseases; Fatigue Syndrome, Chronic; Humans; Killer Cells, Natural; Virus Diseases

Topics: Adolescent; Adult; Ascorbic Acid; Drug Therapy, Combination; Female; Humans; Male; Medicine, Chinese Traditional; Medicine, East Asian Traditional; Middle Aged; Myocarditis; Plant Extracts; Plants, Medicinal; Virus Diseases

Topics: Adjuvants, Immunologic; Antiviral Agents; Ascorbic Acid; Bacterial Infections; Glucans; Humans; Hypersensitivity, Delayed; Immune System Diseases; Inosine; Inosine Pranobex; Levamisole; Lymphocyte Activation; Mycoses; Phagocytosis; Rosette Formation; T-Lymphocytes; Thymus Hormones; Tilorone; Transfer Factor; Virus Diseases

Topics: Ascorbic Acid; Ascorbic Acid Deficiency; Humans; Interferons; Multiple Sclerosis; Virus Diseases

Topics: Ascorbic Acid; Humans; Interferons; Neoplasms; Orthomolecular Therapy; Virus Diseases

Prostaglandin (PG) E1 plays a major role in the regulation of thymus development and T lymphocyte function and the evidence for this is reviewed. The production of PGE1 is dependent on nutritional factors with linoleic acid, gamma-linolenic acid, pyridoxine, zinc and vitamin C playing key roles. Inadequate intake of any one of these will lead to inadequate PGE1 formation and defective T lymphocyte function. Megadoses of any one are likely to be only minimally effective in the absence of adequate intakes of the others. By careful attention to diet it should be possible to activate T lymphocyte function in the large number of diseases including rheumatoid arthritis, various auto-immune diseases, multiple sclerosis, and cancer in which such function is defective. It is possible that T lymphocytes may require both endogenous and exogenous PGE1 in order to function adequately. It is therefore of particular interest that many cancer cells and virally infected cells are unable to make PGE1 because they cannot convert linoleic acid to gamma-linolenic acid. The direct provision of gamma-linolenic or dihomo-gammalinolenic acids in these situations is worthy of full investigation.

Topics: Animals; Ascorbic Acid; Diet; Fatty Acids, Nonesterified; Glucocorticoids; Humans; Immunity, Cellular; Inflammation; Lithium; Neoplasms; Nutritional Physiological Phenomena; Prostaglandins E; T-Lymphocytes; Thymus Gland; Virus Diseases; Zinc

Homo sapiens' gene pool contains a defective gene for the synthesis of the active enzyme protein, L-gulonolactone oxidase(GLO). The absence of GLO in the human liver blocks the normal mammalian conversion of blood sugar into ascorbate, leading to the potentially-fatal "inborn error of carbohydrate metabolism", the genetic disease, Hypoascorbemia (in the older nomenclature- scurvy). To survive, humans need exogenous sources of daily ascorbate. Most mammals have the intact gene for GLO synthesis and produce generous daily amounts of the liver metabolite, ascorbate; for instance, an unstressed 70 Kg goat is capable of producing over 13 grams of ascorbate daily and much more under stress. The recommended dietary allowance of 45 milligrams of ascorbate a day for human adults, now proposed and used by nutritionists, is grossly inadequate to restore Homo sapiens to a normal mammalian ascorbate physiology. To correct fully this human genetic defect and banish epidemic chronic subclinical scurvy requires daily intakes of ascorbate equivalent to, at least, the amounts synthesized by the other mammals. Humans kept on a long term regime of full correction of this birth defect show great salutary benefits in health maintenance, disease therapy and slowing of the aging process. This can be regarded as the creation of a new and more robust, longer-living, tough human sub-species, Homo sapiens ascorbicus, by the biochemical reversal of a primate mutation occurring some 60 million years ago. Some of the practical benefits and pathways of future clinical research are discussed.

Topics: Aging; Alcohol Oxidoreductases; Ascorbic Acid; Ascorbic Acid Deficiency; Genes; Heart Diseases; Humans; Neoplasms; Substance-Related Disorders; Sudden Infant Death; Virus Diseases

Topics: Anti-Bacterial Agents; Ascorbic Acid; Bacterial Infections; Drug Synergism; Humans; Rickettsia Infections; Virus Diseases; Vitamins

Topics: Animals; Ascorbic Acid; Binding Sites; Bird Diseases; Bronchitis; Cells, Cultured; Chick Embryo; Cysteine; Dithiothreitol; Glutathione; Hydroxymercuribenzoates; Kidney; Mercaptoethanol; Neuraminic Acids; Neuraminidase; Newcastle disease virus; Oxidation-Reduction; RNA Viruses; Salicylates; Sulfhydryl Compounds; Swine; Virus Diseases

Topics: Animals; Ascorbic Acid; Cat Diseases; Cats; Picornaviridae; Respiratory Tract Diseases; Tracheitis; Uridine; Virus Diseases

Topics: Ascorbic Acid; Common Cold; Humans; Respiratory Tract Infections; Virus Diseases

Topics: Adenoviridae; Adenoviridae Infections; Antiviral Agents; Ascorbic Acid; Common Cold; Cough; Culture Techniques; Humans; Infections; Orthomyxoviridae; Orthomyxoviridae Infections; Picornaviridae; Respiratory Tract Infections; Virus Diseases

Topics: Adenoviridae Infections; Aminophylline; Ascorbic Acid; Chlamydophila psittaci; Chloramphenicol; Drug Therapy; Epidemiologic Studies; Epidemiology; France; Humans; Influenza, Human; Military Medicine; Orthomyxoviridae; Orthomyxoviridae Infections; Pneumonia; Pneumonia, Viral; Psittacosis; Radiography, Thoracic; Respiratory Tract Diseases; Sendai virus; Serologic Tests; Vaccination; Virus Diseases

Topics: Ascorbic Acid; Virus Diseases; Vitamins

Topics: Animals; Ascorbic Acid; Chick Embryo; Hemagglutination; Hemagglutination Tests; Influenza A virus; Newcastle Disease; Plague; Virus Diseases; Vitamins

Topics: Ascorbic Acid; Crohn Disease; Flavonoids; Ileitis; Virus Diseases; Vitamins

Topics: Ascorbic Acid; Humans; Virus Diseases; Vitamins

Topics: Ascorbic Acid; Infections; Poliomyelitis; Virus Diseases; Viruses; Vitamins